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Objective. There is still debate whether type II endoleaks represent a risk for the patient after EVAR. Treatment policies vary
from fairly conservative to active intervention. In this analysis risk factors for type II endoleak and adverse events during
follow-up were assessed. In addition, risk factors and causes for conversion to open repair and for rupture post-EVAR were
studied.
Methods. The data of 3595 patients, who underwent operation between 1996 and 2002 in 114 European institutions that
collaborated in the EUROSTAR Registry, were assessed. To accurately assess the influence of type II endoleaks patients with
type I, III and combined endoleaks were excluded from the present study cohort.
Results. A combined adverse outcome event consisting of aneurysmal growth, transfemoral reintervention, and
transabdominal secondary procedures (including laparoscopic branch vessel clipping) occurred in 55% in patients with type
II endoleak at 3 years, compared to 15% in patients without any endoleak (p , 0.0001). Conversion to open repair or post-
EVAR rupture was not significantly associated with type II endoleaks. An independent association of device migration and
expansion of the aneurysm with late conversion was observed. The cumulative incidence of aneurysm rupture at 3 years of
follow-up was 1.2% for an annual rate of 0.4%. Variables that significantly and independently correlated with rupture were
size of the aneurysm at preoperative measurement and device migration during follow-up.
Conclusion. Endoleak type II may not be harmless as it was more frequently associated with enlargement of the aneurysm
and reinterventions. Large aneurysms and migration of the device were the main risk factors for rupture. The clinical
implications of these findings may involve more frequent surveillance visits for patients with type II endoleak. Aneurysm
expansion is a clear indication for reintervention. Patients with large aneurysms, 65 mm or larger, may also benefit from a
more comprehensive surveillance schedule.
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Introduction
The feasibility of endovascular abdominal aortic
aneurysm repair (EVAR) and the short-term advan-
tages compared to conventional open surgery are no
longer in doubt. In patients with suitable aortoiliac
anatomy the primary success rate, represented by
successful access at endograft deployment, is almost
98%.1 However, new complications have plagued the
stentgraft approach. Failure to totally exclude the
AAA from continued perfusion and pressurisation,
defined as ‘endoleak’, remains a potential shortcoming
of endoluminal repair,2,3 and rupture of the aneurysm
represents the most dramatic evidence of treatment
failure.4 – 8 Conversion to open surgery is either
performed for manifest rupture of the aneurysm or
for impending rupture indicated by radiological or
ultrasound studies. In almost any current overview of
EVAR the need for intensive surveillance to identify
indicators for an increased risk of rupture is
emphasised.
Previous assessments, reported from the EURO-
STAR collaborators group have demonstrated that the
risk of rupture after EVAR, and the need for secondary
interventions including conversions to open repair is
significantly less in patients with collateral reperfusion
(type II) endoleaks than with type I (attachment site
endoleak), type III (midgraft leak resulting from
disconnection of modular systems or from graft
defects), and combined types I and III.9 Moreover,
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the rate of enlargement of aneurysms appeared
distinctly lower in patients with type II endoleaks
than with other endoleaks.10 The general recommen-
dation from the EUROSTAR reports as well as from
others is that type I and III endoleaks require prompt
repair. The policy in case of type II endoleaks is more
open to debate with proponents of early interventions
as well as of a conservative approach.9,11,12 In this
latter view the patient should be followed by regular
imaging and intervention performed only in case of a
significant increase of aneurysm size. With the
preferentially non-interventing policy the question
remains whether persisting collateral reperfusion
endoleak poses the patient to a greater risk of post-
EVAR complications such as rupture or secondary
interventions than patients without endoleaks. In the
present analysis risk factors for isolated type II
endoleak and adverse events during follow-up, in
particular enlargement of the aneurysm, need for
secondary interventions and occurrence of rupture
were investigated. In addition risk factors and causes
for conversion to open repair and for rupture post-
EVAR were assessed. For this analysis an updated and
selected portion of the EUROSTAR series was used. As
the presence of type I, III and combined endoleaks
tend to overtone the effect of other adverse factors in
the statistics8 – 10,13,14 we excluded patients with these
endoleaks from the present study cohort.
Methods
Organisation and patient selection
Details on the organisation of the registry and the data
collection have been published in previous articles.1,8
Clinical events and findings at image studies, most
frequently CT examination, were recorded during
follow-up at 1, 6, 12, 18, and 24 months and annually
thereafter. In the present study a selected portion of the
entire EUROSTAR cohort was studied to avoid
reiteration of previous analysis. Important exclusion
criteria were: (1) all patients of whom the data had
been collected retrospectively (enrolment before Sep-
tember 1996), (2) patients treated with the first
generation of stentgrafts, as the performance of these
older models may not reflect results of the more recent
models, (3) patients in whom a type I, III or combined
endoleak was observed during follow-up. This cat-
egory is known to be considerable risk to develop
adverse events and the need of prompt reintervention
has been extensively emphasised in the existing
literature, (4) patients with infrequently used device
labels, i.e. less than 100 cases in the database, as small
subgroups may preclude a useful analysis. One
hundred and fourteen centers contributed the patient
data for this study cohort between July 1996 until June
2002 (see Appendix).
Clinical data
All patients had a full medical history and physical
examination, contrast enhanced computerised tom-
ography (CT) and angiography. Patients were evalu-
ated with respect to age, sex, smoking, obesity, and
fitness for conventional open repair, and physical
status classification as defined by the American
Society of Anaesthesiologists (ASA). The experience
of the surgeon at the type of device used was also
evaluated. Other data included in the analysis
regarded aneurysm morphology: neck diameter and
length, aneurysm diameter, and angulation. The type
of aortic device was also used for comparison of
outcome events. Endoleak was detected using regular
imaging of the abdominal aorta during follow-up.
Endograft surveillance was performed using the
following imaging techniques: contrast enhanced
computer tomography (in 84%), angiography (in
4%), magnetic resonance angiography (in 3%), duplex
ultrasound examination (in 8%).
Type II endoleaks were differentiated into persistent
and temporary endoleaks. A persistent endoleak was
defined as positive identification of endoleak at two
occasions with not more than one visit with a negative
imaging study in between.
Outcome events: transabdominal interventions
included conversions to open surgery, endoscopic
clipping of IMA, lumbar and hypogastric arteries,
open procedures, related to the infrarenal aorta or iliac
arteries.
Aneurysm expansion was defined if the maximum
transverse diameter increased by 8 mm or more
during any follow visit compared to the preoperative
measurement.
Analysis
The clinical features of the patients with endoleak type
II were compared to patients without endoleak.
Discrete data were analysed using Chi-square test
and Fisher correction in case of small subgroups. A
multivariate analysis was performed by selecting
variables found to be significantly associated with
events in the univariate analysis. Continuous variables
were compared using the Mann–Whitney U-test. Life
table analysis was used to assess incidence rates of
adverse events during follow-up. The incidence of
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time-dependent variables in patient groups was
compared using a log-rank test. In case of multivariate
analysis of time dependent variables a Cox pro-
portional hazard model was used. All statistical
analyses were performed using Statistical Analysis
Software (SAS Institute Inc. 8.0) program (Cary, NC,
USA).
Results
Type II endoleaks
Of the overall cohort of 4613 patients, that were
included in the EUROSTAR database as of June 2002,
1018 were excluded because of retrospective enrol-
ment, stentgraft models other than AneuRx, Excluder,
Talent, Vanguard or Zenith, the presence of a type I, III
or any combination of endoleaks during follow-up.
This study cohort consisted of 3595 patients, of whom
320 (9%) had an isolated type II endoleak at the 1st
month imaging examination, or at any time thereafter
(group A), and 3275 (91%) patients who did not have
an endoleak at any time during follow-up (group B).
The mean duration of follow-up of this cohort was 15
months (0–72).
Preoperative patient characteristics, aorto-iliac mor-
phologic features, operative details, and device brands
are summarised in Tables 1 and 2 and significant
correlations with type II endoleaks indicated.
It is of note that an ankle-arm blood pressure index
of 0.87 or less, current smoking, and poor renal
function only in the univariate analysis were associ-
ated with a lower prevalence of type II endoleaks
(Table 1). Variables that independently correlated with
a higher prevalence of type II endoleaks in the
multivariate analysis included age of the patient,
patent IMA and length of the infrarenal neck (Table 3).
Events during follow-up that occurred significantly
more often in patients with type II endoleak were:
aneurysm growth (p ¼ 0:003, Table 3, Fig. 1), the need
for a transfemoral reintervention (p ¼ 0:001; Table 3),
and transabdominal secondary procedures (only
significant in the univariate analysis, p ¼ 0:02). Fig. 2
represents these three adverse events as a combined
adverse outcome, which occurred far more frequently
in patients with type II endoleak ðp , 0:0001Þ: Late
rupture occurred in 12 patients without, and in only
one patient with a type II endoleak (not significant).
The incidence of late deaths and conversion to open
repair was not significantly different in the two study
groups.
Conversion to open repair
Conversion to open repair was performed in 71
patients (2%), of whom 45 had an early conversion
(within the first month), and 26 a late conversion. The
mean period between EVAR and late conversion was
32 months (3–60). The maximum transverse diameter
was 61 mm in patients with late conversion and
57 mm in patients without conversion. However, this
difference was not significant ðp ¼ 0:09Þ: Severe angu-
lation of the aneurysm was more frequent in patients
with early conversion (23%) than in patients without
conversion (11%, p ¼ 0:018). Early conversions were
more frequently required in the period from 1996 to
1998 than in the period from 1999 to 2002 (2.5% vs.
0.7%, respectively, p , 0:0001). The incidence of late
conversions was not statistically different for the first
and second period regarding the year of the initial
EVAR-procedure, although the difference was near the
level of significance (4.1% vs. 0.5% at 4 years
respectively, p ¼ 0:056).
Of the different device brands the use of Talent-
grafts correlated with a higher incidence of early
conversion ðp ¼ 0:02Þ: None of the devices were
associated with an increased rate of late conversion.
Type II endoleaks were observed during follow-up
in 19% of the patients with late conversion compared
to 9% of the patients without conversion. This
Table 1. Characteristics, comorbidity, and aorto-iliac morphologic factors.
Group A, type II endoleak (320 pts) Group B, no endoleak (3275 pts)
Age (mean-years, range) 73 (50–93) 71 (37–100) p ¼ 0:002
Male sex 92% 94%
ASA physical status $3 57% 54%
Ankle/arm systolic blood pressure index #0.87 11% 22% p ¼ 0:0002
Current smoking 16% 26% p ¼ 0:0002
Renal insufficiency 15% 20% p ¼ 0:02
Infrarenal neck diameter (mean—mm) 23 23
Length of infrarenal neck (mean—mm) 29 27 p ¼ 0:0001
AAA diameter (mean—mm) 57 57
Inferior mesenteric artery patent 47% 36% p ¼ 0:0004
Variables without indicated p-value had a p . 0:05.
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difference was not significant. In addition, the obser-
vation of proximal, midgraft and distal endoleaks
during follow-up did not correlate with conversion.
Observed events during follow-up, that correlated
in the univariate analysis with the need for late
conversion included stenosis or thrombosis of the
device (in 23% of patients with late conversion,
p ¼ 0:02), migration of the device (in 54%,
p , 0:0001), aneurysm expansion (in 25%, p ¼ 0:017),
and rupture of the aneurysm (in 23%, p , 0:0001). For
migration, aneurysm expansion an independent
association with late conversion was observed (Table
3).
The first-month mortality associated with early
conversion was 13% (6/45) compared to 2.3% in
patients without conversion ðp , 0:0001Þ: Mortality
during the entire follow-up period in patients with late
conversion was 7.7% (2/26) compared to 7.4%
(261/3524) in patients without conversion (ns).
Rupture of the aneurysm
In this study cohort 14 patients experienced rupture of
the aneurysm after EVAR. Rupture occurred at the
mean of 24 months (0–48) from the initial operation.
The cumulative incidence of rupture at 3 years of
follow-up was 1.2%. Eight of the 14 patients had
preoperatively a diameter of 65 mm or greater and this
diameter had not decreased at the time of rupture in
five of these patients. Of the variables assessed at
baseline by univariate analysis the maximum aneur-
ysm diameter correlated significantly with post-EVAR
rupture (70 mm (55–105) in patients with rupture vs.
57 mm, (30–145), p ¼ 0:004). Significant angulation of
the infrarenal neck and associated common iliac
aneurysm had borderline significant correlations
with rupture (p ¼ 0:05 and 0.03, respectively). At
multivariate analysis the preoperative aneurysm
diameter was the only independent correlating vari-
able (Table 3). The year in which EVAR was performed
had no correlation with the risk of rupture. None of the
endograft models was associated with an increased
risk of rupture.
Of follow-up data migration of the device correlated
significantly with rupture (in 29% of patients with
rupture vs. 3.2%, p ¼ 0:0017). There was a weak
correlation between thrombosis and stenosis of
devices with rupture ðp ¼ 0:03Þ: No correlation
between endoleak type II and aneurysm was demon-
strated. In the multivariate model migration was the
Table 2. Device brands, operative details, and findings at completion angiography.
Group A, type II endoleak (320 pts) Group B, no endoleak (3275 pts)
AneuRx 77 (9%) 756 (91%)
Excluder 35 (10%) 314 (90%)
Talent 45 (6%) 730 (94%) p ¼ 0:0006
Vanguard 94 (12%) 665 (88%) p ¼ 0:0001
Zenith 69 (8%) 810 (92%)
Embolisation of side branches 13% 9% p ¼ 0:016
Blocking of one or two hypogastric arteries 22% 16% p ¼ 0:016
Reperfusion endoleak, lumbar or IMA 21% 7% p ¼ 0:0001
Variables without indicated p-value had a p . 0:05:
Table 3. Multivariate analysis of type II endoleak, late conversion and post-EVAR aneurysm rupture.
Event Category of variables Variable with independent correlation p-value Confidence interval
Type II endoleak Baseline Age of patient 0.001 1.01–1.06
Preoperative patency of IMA 0.031 1.03–1.99
Length of infrarenal neck 0.006 1.01–1.03
Current smoking 0.008 0.38–0.87
Ankle–arm BP index #0.87 0.0007 0.23–0.68
Operation Coil embolisation of side branches 0.014 1.10–2.30
Patent IMA or lumbar arteries on
operative arteriogram
,0.0001 2.21–3.82
Follow-up Expansion of aneurysm 0.003 1.20–2.51
Transfemoral reintervention ,0.0001 2.52–4.58
Late conversion to open repair Follow-up Device migration ,0.0001 4.11–21.35
Expansion of aneurysm 0.024 1.16–8.32
Aneurysm rupture ,0.0001 6.79–50.20
Rupture of aneurysm Baseline Aneurysm diameter ,0.0001 1.04–1.09
Follow-up Device migration 0.019 1.26–13.37
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only variable, that maintained a significant correlation
with rupture (Table 3).
Eight of the patients with rupture died in associ-
ation with post-EVAR rupture, for a mortality of 57%,
compared to a combined early and late mortality rate
of 10% in patients without rupture ðp , 0:0002Þ:
Discussion
The less invasive nature of the procedure and the
generally satisfactory early results, have made endo-
vascular AAA-repair an appealing therapeutic
alternative to most patients with AAA. Studies that
compared the outcome of EVAR with open surgery
have consistently demonstrated a significant reduction
in morbidity with endovascular repair.15 – 18 In a recent
report by Arko et al. aneurysm related death showed a
difference of 5% combined early and late aneurysm
related death at 3 years of follow-up in favour of
EVAR.19 This difference nearly reached statistical
significance. However, this study, like previous com-
parative studies, was not randomised and patient
selection may have skewed the outcome in the study
groups in one or another way. Although the prospects
of EVAR look exceedingly bright at this time,
recognition of risk factors for adverse events, such as
the need for conversion to open surgery and late post-
EVAR rupture, may lead to further improvement of
the techniques. In previous publications, based on the
EUROSTAR registry, risk factors for proximal device
migration and device-related endoleaks type I and III
have been reported.9,10,20,21 In the present study, the
significance of the most common endoleak, type II,
was assessed in greater detail, with regard to severe
outcome events. To make the conclusions of the study
more applicable to current practice, retrospectively
enrolled patients, in whom predominantly endografts
were used that are not available for many years were
also excluded from the analysis. In these previous
publications the effect of endoleaks other than type II
and factors typically associated with older graft
versions on conversion or rupture were quite domi-
nant.8,10,14 The present modifications in the compo-
sition of the study cohort were intentionally made to
highlight the effect of other risk factors. It is felt in the
EUROSTAR organisation that a continuous updating
and renewal of analysis are most valuable to increase
insight in the technique, and assumingly may improve
guidelines for patient selection and surveillance.
Fig. 1. Incidence of aneurysm enlargement in patients with and without type II endoleak. The difference is significant
ðp ¼ 0:003Þ.
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Of the preoperative patient and morphologic
factors age of the patient, length of the infrarenal
neck and patency of IMA were shown to be associated
with increased occurrence of type II endoleak. Except
for the latter condition one may only speculate on the
biologic basis for these correlations. The reversed
association (type II endoleaks were less frequently
observed) of ABI # 0.87, and current smoking is
surprising and had not been observed previously.
One may reason that these factors are markers of
peripheral arterial occlusive disease, perhaps associ-
ated with more severe atherosclerosis of side branch
vessels. This condition may lead to more frequent
occlusion of collaterals compared to patients with
more distensible lumbar, hypogastric and inferior
mesenteric arteries. Moreover, current smoking is
known to cause changes in the coagulation profile of
the blood,22 which also may influence the tendency of
spontaneous occlusion of small vessels. This reasoning
seems in agreement with the adverse effect of
therapeutic Warfarin in spontaneous closure of type
II endoleak as was recently documented by Fairman
et al.23
Some groups have adopted an aggressive approach
to type II endoleaks in that persisting leaks are coil
embolised, irrespective whether any enlargement of
the aneurysm sac is observed.11,24 The rational behind
this approach is based on in vitro experiments, in
which open collateral vessels maintained systemic
pressure within an excluded sac.25 Several clinical
studies also have suggested that aneurysm growth
and even rupture of excluded aneurysms, surgically or
by stentgraft, can be caused by patent collateral
pathways.7,26,27
In the present study we demonstrated that a patent
IMA at preoperative imaging was significantly associ-
ated with late collateral endoleak. Other groups made
similar observations of preoperative branch vessel
patency and increased rates of type II endoleak
following EVAR.28,29 Considering these observations,
prophylactic branch embolisation before or during
EVAR may seem a rational approach to avoid type II
endoleak development. However, no reduction of
endoleaks was documented in a number of studies
in which this approach was attempted.30,31 In the
present study coil embolisation before or during EVAR
correlated with an increased rate of type II endoleaks.
This finding supports the supposition that complete
Fig. 2. Incidence of combined outcome event consisting of aneurysm enlargement, transfemoral and transabdominal
secondary intervention (with univariate comparison) in patients with and without type II endoleak. The difference is
significant ðp ¼, 0:0001Þ.
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Table A1. Participants from 114 institutions who contributed the data of this EUROSTAR Study.
Austria Norway
Vienna Prof. G. Kretschmer Oslo Prof. A. Kroeze
Belgium Oslo Dr K. Krohg-Soerensen
Aalst Dr J. de Coster Trondheim Prof. H. Myhre
Aalst Dr Degrieck Poland
Antwerpen/Wilrijk Dr M. van Betsbrugge Lublin Prof. J. Michalak
Assebroek/Brugge Dr H. Tubbax Warsaw Dr M.L. Nowicki
Bonheiden Dr P.M.A.J. Peeters Spain
Bruxelles Dr R. Verhelst Barcelona Dr V. Riambau
Gilly Dr H. Massin Barcelona Dr M. Cairols
Kortrijk Dr L. van Lysebeth Barcelona Dr J. Escudero Rodriguez
Leuven Prof. A. Nevelsteen Donostia San Sebastian Dr M. de Blas
Lommel Dr M. Mattens La Coruna Dr R. Segura
Mechelen Dr Y. Tielemans Leon Dr R. Fernandez-Samos Gutierrez
St.Truiden Dr F. van Elst Lugo Dr J.R. Pulpeiro
St.Truiden Dr L. Verougstraete Madrid Dr D. Tagarro
Turnhout Dr P. Stabel Madrid Dr E. Criado
Vilvoorde Dr E. Sebrechts Madrid Dr Sanchez-Corral
Denmark Madrid Dr J. Urbano
Copenhagen Dr L. Jo¨rgensen Madrid Dr F. Acin
Odense Dr P. Justesen Pamplona Dr L. Fernandez Alonso
France Valladolid Dr V. Gutie´rrez Alonso
Draguignan Dr C. Mialhe Sweden
Grenoble Dr J.L. Magne Lund Prof. L. Norgren
Lille Cedex Dr M.A. Vasseur Orebro Dr Th. Nordh Larzon
Lyon Dr B. Age Switzerland
Lyon Dr P. Feugier Bern Dr J. Schmidli
Marseille Dr Ph. Piquet Zurich Dr M. Enzler
Montpellier Prof. C. Marty-Ane The Netherlands
Nancy Dr C. Amicabile Alkmaar Dr H.A. van Dijk
Nanterre Dr J. Marzella Amsterdam Dr R. Balm
Nimes Dr Y. Cardon Amsterdam Dr W. Wisselink
Paris cedex Prof. J.C. Gaux Amsterdam Dr Vahl
Paris Creteil Cedex Prof. J.P. Becquemin Apeldoorn Dr E.G.J. Vermeulen
St Etienne Prof. J.P. Favre Arnhem Dr W.R. de Vries
St Laurant du Var Prof. P. Kreitmann Delft Dr J. Koning
Toulouse Prof. H. Rousseau Den Haag Dr J.C.A. de Mol van Otterloo
Toulouse cedex Dr C. Giraud Den Haag Dr H. van Overhagen
Germany Dordrecht Dr R.P. Tutein Nolthenius
Bonn Dr A. Viehofer Eindhoven Dr J. Buth
Dusseldorf Dr R. Kolvenbach Enschede Dr R.H. Geelkerken
Frankfurt Prof. W. Stelter Geldrop Dr F.Th.P.M. van der Linden
Frankfurt Prof. H. Sievert Groningen Dr E. Verhoeven
Freiburg Dr P. Uhrmeister Groningen Dr H.R. Dop
Hamburg Prof. H. Kortmann Maastricht Dr G.W.H. Schurink
Hanover Dr G. Voshage Nieuwegein Dr F. Moll
Kempten Dr Antoni Nijmegen Dr W.B. Barendrecht
Koblenz Dr R. Wickenho¨fer Nijmegen Prof. J. van Vliet
Mainz Dr C. Duber Rotterdam Dr A. de Smet
Marburg Dr H. Alfke Rotterdam Dr M. van Sambeek
Munich Prof. P.C. Maurer Rotterdam Dr A.C. van der Ham
Oldenburg Dr C. Ratusinski Tilburg Dr Hamming
Ulm Dr Pamler Tilburg Dr S. Kranendonk
Greece Utrecht Dr J. Blankensteijn
Psihico Athens Prof. P. Balas Veldhoven Dr J.A. Charbon
Ireland Zwolle Dr P. Jo¨rning
Dublin Prof. Shanik United Kingdom
Israel Bournemouth Dr S. Darke
Tel Aviv Prof. B. Morag Bristol Dr R. Baird
Italy Chester Dr G. Abbott
Perugia Prof. P. Cao Glasgow Dr R. Edwards
Roma Dr M. Scoccianti Hull Dr D. Ettler
Luxembourg Liverpool Dr P. Harris
Luxembourg Dr P. Berg London Dr J. Wolfe
Monaco Manchester Dr R. Asleigh
Monaco Dr C. Mialhe New Castle-Upon-Tyne Dr M.G. Wyatt
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obliteration of all patent branches often fails. Whether
prophylactic (at the time of EVAR) rather than
therapeutic coil embolisation of endoleaks will result
in a durable reduction of blood pressure within the
aneurysmal sac remain indeterminate. Some animal
experiments showed that pressures within the aneur-
ysmal sac remained unchanged after coil implan-
tation.32 However, the same group demonstrated later
in an in vivo model that long narrow channels
mimicking collateral vessels could be obliterated
more effectively by catheter intervention than chan-
nels representing device attachment related endo-
leaks.33 Whatever the outcome of these experiments,
several studies including the present one, do not
suggest that secondary intervention by catheter
technique or laparoscopic clipping (a recently popular
alternative) are indicated for type II endoleaks unless
the aneurysm clearly shows expansion.9,10,34
Enlargement of the aneurysm is often considered
evidence of treatment failure. While other reports
often use a 5 mm diameter increase on CT, as the
threshold to define growth, we considered 8 mm or
greater as the threshold to indicate a significant
change. It was assumed that the interobserver varia-
bility in a registry, without use of core-lab monitoring,
would be larger than in single institutional series. In
patient without endoleak freedom-from-enlargement
of the aneurysm was observed in 93% at 3 years, while
the incidence was 81% in patients with type II
endoleak. These findings are unique for the EURO-
STAR database, primarily because other studies
reporting on aneurysm size changes, made no distinc-
tion between the different types of endoleaks.10,35,36
Early conversion was substantially less frequently
performed after 1998 considering a rate of 0.7%
compared to 2.5% in the previous years. This reflects
a changing attitude towards the indication to resolve
intraoperative complications, such as access problems
and device migration during EVAR. Reports from May
et al. and subsequent studies including one by the
EUROSTAR group, have emphasised the high mor-
tality associated with primary conversion.14,37 Late
conversions were primarily performed for rupture,
migration or aneurysm enlargement.14 Although con-
versions were more frequently performed in patients
with type II endoleak than in patients without
endoleak, this difference was not significant. The
mortality associated with late conversions was 8%
(2/26), which compared favourably with other current
multicenter series.38
The proportion of patients experiencing post-EVAR
rupture in the study cohortiously influenced by the
exclusion of patients with type I and III endoleaks. In
addition this rate is dependent of the duration of
follow-up. The entire EUROSTAR cohort (4613)
including patients with early stentgraft versions,
retrospectively enrolled patient data and all types of
endoleaks involved 37 patients with rupture (0.8%) as
of June 2002. Details on this cohort will be published
shortly. The report by Harris et al., which was
submitted in March 2000, involved 14 patients out of
2464 with aneurysm rupture, for an annual cumulative
rupture rate of approximately 1%.8 In the present
study the annual rate of rupture was 0.4. However, the
patient selection described above makes these figures
incomparable. The overall mortality after rupture was
57%, a figure that is fairly typical for ruptured AAA.
With regard to the cause of rupture it was not
surprising that the preoperative aneurysm diameter
and migration during follow-up correlated indepen-
dently with post-EVAR aneurysm rupture. Migration
of endografts may lead to sudden pressurisation and
rupture of aneurysm sacs.
Conclusion
A selected patient cohort was examined excluding the
influence of type I and III endoleaks, which have a
notorious reputation to be associated with adverse
outcome. The clinical implications of this study are
several. Endoleak type II may not be harmless, as it
was more frequently associated with enlargement of
the aneurysm and reinterventions. Our findings
suggest that more frequent surveillance examinations
are indicated than in patients without collateral
endoleak. The indication for reintervention is primar-
ily dictated by documented aneurysm expansion.
Primary conversion is now generally perceived to be
a dangerous procedure, and its use has been markedly
reduced in the recent years. Large aneurysms and
migration of the device were the main risk factors for
rupture. More comprehensive surveillance of aneur-
ysms of 65 mm or larger and prompt recognition and
treatment of device migration are mandatory.
Appendix
Table A1
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